Using autologous cell therapy to treat knee osteoarthritis pain and inflammation
Official title: Safety and Effectiveness of Autologous Regenerative Cell Therapy on Pain and Inflammation Associated With Osteoarthritis of the Knee
Run by VivaTech International, Inc. · NCT02844751 · Data updated 2026-11-12
This study is testing if a new cell therapy using your own body’s cells can help relieve pain and swelling in people with knee osteoarthritis.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 4000 (estimated) |
| Sponsor | VivaTech International, Inc. Industry-sponsored |
| Locations | 1 site (Grove City, Pennsylvania) |
| Status | Recruiting |
| Started | July 2015 |
| Main results expected | August 2026 |
| Study ends | August 2026 |
| Registry record updated | October 14, 2025 |
| Trial ID | NCT02844751 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-90 with grade 2 or higher osteoarthritis of the knee and a history of knee pain for over 6 months.
✕Probably not a fit
Patients with recent cancer diagnoses, significant cardiovascular issues, or other serious health conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical study aims to evaluate the safety and effectiveness of autologous regenerative cell therapy for patients suffering from knee osteoarthritis. It involves a prospective open-label design with an initial cohort of 50 patients receiving injections of autologous Stromed and Platelet Rich Plasma (PRP) to alleviate pain and inflammation. Patient outcomes will be monitored through MRI scans, laboratory tests for inflammation markers, and various questionnaires assessing knee function and quality of life over a follow-up period of up to 6 months. The study will eventually expand to include a larger sample size of 4,000 patients for further validation.
Why it matters
Potential benefit: If successful, this therapy could significantly reduce pain and inflammation in patients with knee osteoarthritis, potentially delaying the need for knee replacement surgery.
How similar studies have gone: While the use of autologous cell therapies is gaining traction, this specific approach is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with indication of Osteoarthritis, grade 2 or more. Can be from degeneration or chronic injury. 2. Patients range from 18-90 years of age. 3. Patients must be able to comply with treatment plan, laboratory tests and periodic interviews. 4. Patients with adequate renal function, Creatinine ≤ 1.5 mg/dl. 5. Patients with adequate cardiac and respiratory function. 6. Patients with adequate blood coagulation activity, PT(INR) \< 1.5, APTT 7. Patients must have adequate immune system function, with no known immunodeficiency disease. 8. Greater than 6 months knee pain on the index side (left or right knee). Exclusion Criteria: 1. Neoplastic cancer within 5 years prior to screening, except for cutaneous basal cell or squamous cell cancer resolved by excision 2. Presence of clinically significant acute or unstable cardiovascular and cerebrovascular (stroke). 3. Diagnosis of a transient ischemic attack in the 6 months prior to screening. 4. Patients infected with hepatitis B, C or HIV. 5. Patients with Body Mass Index (BMI) \> 40kg/m2 6. Presence of active infection. 7. Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the investigator would render a patient unsuitable to participate in the study. 8. Conditions/therapies/factors which could confound or interfere with the evaluation of pain/mobility including, but not limited to: 1. Knee instability. 2. A varus/valgus deformity of more than 10o, a deformity requiring osteotomy or complex surgery. 3. Gout or pseudo gout 4. Treatments with strong opioid drugs in the previous 4 weeks for other pain rather than knee osteoarthritis 5. Corticosteroid injection at treatment site within 1 month 6. Consistent use of NSAIDs within 48 hours of procedure.
Where it's running
-
VivaTech International, Inc.
Grove City, Pennsylvania, United States Recruiting
Study contacts
- Principal investigator: Mark LoDico, MD — Advanced Regenerative Medicine
- Study coordinator: Scott M Herkes, MBA
- Email: scott.herkes@gmail.com
- Phone: 855-984-8287
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Autologous adipose-derived stem cell injections for knee osteoarthritis
We’re testing whether injecting a patient’s own fat-derived stem cells into the knee can help people with knee OA feel less pain and move better, compared with a standard hyaluronic acid treatment.
-
Early wear of a Vitamin E-infused liner in a dual-mobility hip replacement
This study tests whether a Vitamin E-infused liner in a dual-mobility hip implant wears as little as a conventional liner over two years in adults needing hip replacement.
-
Preoperative Music to Ease Anxiety Before Hip or Knee Replacement
Patients awaiting hip or knee replacement listen to their own music through noise‑canceling headphones to see if it lowers preoperative anxiety.
-
Weight-bearing dangling exercises vs VMOb NMES for knee osteoarthritis
This study tests whether weighted dangling exercises or VMOb muscle NMES help people with knee osteoarthritis.
-
Post-op prednisone vs standard steroid regimen after knee or hip replacement
This study tests a 5-day oral prednisone course after knee or hip replacement to see if pain, swelling, and glucose control are better or different than the usual intraoperative steroid approach.
-
AI-based prediction of five major diseases using integrated health data
Researchers are testing an AI model to see if they can predict the onset of five major diseases in adults 30–65 by combining medical records with biospecimens and lifestyle data.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.